Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 7,084 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Breast Cancer Clear all

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: venlafaxine; Drug
Lead sponsor: Indiana University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Locally Advanced or Metastatic Solid Tumor
Interventions: Rebastinib, Paclitaxel; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 10 more

Conditions: Metastatic Non-Small Cell Lung Carcinoma, Metastatic Colorectal Cancer, Metastatic Breast Cancer
Interventions: Blood-based cell-free cfDNA qPCR assay; Diagnostic Test
Lead sponsor: Cadex Genomics; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 11
States / cities: Little Rock, Arkansas • Sunnyvale, California • Denver, Colorado + 7 more

Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma
Interventions: CTX-8371; Drug
Lead sponsor: Compass Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • Palo Alto, California • Margate, Florida + 8 more

Conditions: Breast Cancer Metastatic
Interventions: Avasopasem; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Breast Neoplasm
Interventions: Paclitaxel, Doxorubicin, Cyclophosphamide, G-CSF; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma, Soft Tissue Sarcoma
Interventions: LY3039478, Taladegib, Abemaciclib, Cisplatin, Gemcitabine, Carboplatin, LY3023414; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: Miami, Florida • Detroit, Michigan • New York, New York + 1 more

Conditions: Female Breast Cancer
Interventions: docetaxel + cyclophosphamide + pegfilgrastim; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation
Interventions: LP-184, Olaparib, Nivolumab & Ipilimumab; Drug
Lead sponsor: Lantern Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Springdale, Arkansas • Indianapolis, Indiana • Louisville, Kentucky + 4 more

Conditions: Breast Cancer
Interventions: MRI, CESM; Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 30 Years and older · Female only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor
Interventions: BEZ235 + MEK162; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Breast Cancer
Interventions: FFDM Plus DBT, FFDM; Device
Lead sponsor: Fujifilm Medical Systems USA, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 4
States / cities: Scottsdale, Arizona • Rochester, New York • Chapel Hill, North Carolina + 1 more

Conditions: Breast Cancer
Interventions: high performance liquid chromatography, laboratory biomarker analysis, spectroscopy; Other · Procedure
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Up to 120 Years · Female only
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Placebo, Valproic Acid (VPA), Questionnaires, Pill Diary, Drainage Diary; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer Awareness
Interventions: Not listed
Lead sponsor: Feminai; Industry
Eligibility: 25 Years to 75 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Frisco, Texas

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver, Prognostic Stage IV Breast Cancer AJCC v8
Interventions: Y-90 SIR-Spheres, Yttrium-90 Microsphere Radioembolization, Systemic Therapy; Device · Procedure · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma, Gastric Adenocarcinoma, Endometrial Adenocarcinoma, Triple Negative Breast Cancer, Ovarian Cancer, Prostate Cancer
Interventions: APL-5125; Drug
Lead sponsor: Apollo Therapeutics Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Duarte, California • Irvine, California • Sarasota, Florida + 6 more

Conditions: Triple Negative Breast Cancer, Breast Cancer
Interventions: Trilaciclib, Cylophosphamide, Doxorubicin, Paclitaxel, Carboplatin (Investigator discretion), Pembrolizumab (Investigator discretion); Drug · Biological
Lead sponsor: G1 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 7
States / cities: Los Alamitos, California • Santa Monica, California • Whittier, California + 4 more

Conditions: Breast Cancer, Arthralgia
Interventions: Education and exercise intervention, Education and General Exercise; Behavioral
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Carcinoma, Pain, Radiation-Induced Dermatitis, Stage 0 Breast Cancer
Interventions: Curcumin-based Gel, Dermatologic Complications Management, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration; Drug · Procedure · Other
Lead sponsor: Gary Morrow; Other
Eligibility: 21 Years and older · Female only
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Newark, Delaware • Decatur, Illinois • Minneapolis, Minnesota + 3 more

Conditions: Breast Cancer, Prostate Cancer, Body Composition, White Adipose Tissue Inflammation
Interventions: DEXA Scan, Godin Leisure Time Exercise Questionnaire (GLTEQ); Device · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 9
States / cities: Milford, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: vorinostat, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Duarte, California

Conditions: Breast Cancer, Opioid Use
Interventions: Methadon; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer

Venlafaxine for Hot Flashes After Breast Cancer

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Dose Dense TC + Pegfilgrastim Support for Breast Cancer

Study of LP-184 in Patients With Advanced Solid Tumors

Comparison of Contrast-enhanced Spectral Mammography (CESM) to MRI in Screening High Risk Women for Breast Cancer

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

Pilot Mammography Reader Study to Assess Breast Cancer Detection in FFDM Plus DBT Versus FFDM Alone

Nutrition-Related Biomarkers in Predicting Breast Cancer Risk in Women

Study of Valproic Acid (VPA) vs Placebo to Shorten Time of Indwelling Pleural Catheter

Breast Mapping and Detection of Suspicious Breast Lesions Using Feminai

Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer

Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer

Body Composition and White Adipose Tissue Inflammation

Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer

The Impact of Intraoperative Methadone on Postoperative Opioid Use